NRG-GY029, "A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) with PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients with Recurrent Platinum Resistant Ovarian, Fallopian, Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy" (NCT TBD)

Is this Study for You?

Let's Get Started!



Type of Study



University of Colorado Hospital

Principal Investigator
Photograph of Lindsay Brubaker,  MD

Lindsay Brubaker, MD

Study ID

Protocol Number: 22-1568

More information available at NCT05295589

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers